Neuland Laboratories Limited

Neuland Laboratories Ltd share price declined by 1.64% to Rs 19288.35 after the company's net profit tumbled by 30.56% to Rs 147.67 crore, while revenue from operations reduced 17.35% to Rs 641.58 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 5.74%. It has improved by 0.41% over last one week and advanced by 11.45% in last one month while the market capitalization of Neuland Laboratories Ltd has slipped by 2.17% and 11.49% in the same period respectively. Profit before tax (PBT) of Neuland Laboratories Ltd stood at Rs 197.85 crore in Q2 FY26, rallying 1026.07% year-on-year, and nosediving by 31.18% quarter-on-quarter. EBITDA came in at Rs 214 crore, surging by 705.11% YoY and tanking 27.29% sequentially. Total expenses softened by 9.87% to Rs 445.25 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 228.77 crore, slightly declining by 0.88% YoY, while employee benefits expense was at Rs 106.43 crore, expanding by 8.08% YoY. For the TTM ended FY26, revenue from operations surged 36.98% to Rs 2022.99 crore, while net profit saw a strong growth of 39.94% to Rs 364.0 crore, compared to previous TTM. EBITDA jumped by 32794% to Rs 544.33 crore, and PBT witnessed a strong rise of 41.19% to Rs 488.98 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 346.68 crore in FY26, as against Rs 317.4 crore in FY25. Neuland Laboratories Ltd soared by 47.54% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.20% during the same period.

Neuland Laboratories Limited (NSE: NEULANDLAB; BSE:524558) announced financial results for the quarter ended June 30, 2026, reporting total income of Rs 650.1 crore, up 116.3% year-over-year, and an EBITDA of Rs 231.1 crore, a 448.2% increase compared to the same period last year. The company's profit after tax for the quarter was Rs 147.4 crore, a 975.0% increase year-over-year, with an earnings per share of Rs 114.9. Neuland Laboratories will hold an earnings call at 17:30 hrs. IST on Wednesday, August 5, 2026, to discuss the company’s performance.

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Neuland Laboratories has received affirmation in credit ratings for bank facilities at IND A+/ Positive / IND A1.

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the enhancement of capacity at its Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. Existing capacity - 256 KL Existing capacity utilization - 91% Proposed capacity addition - 120.5 KL Period for capacity addition - within 12-18 months Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director of the Company, categorized as Non-Executive Non-Independent, w.e.f. 12 May 2026.

Neuland Laboratories has fixed 24 July 2026 as record date for purpose of determining the shareholders eligible to receive final dividend of Rs 34 per equity share of Re 10 for FY 2026.

Net profit of Neuland Laboratories rose 664.72% to Rs 212.67 crore in the quarter ended March 2026 as against Rs 27.81 crore during the previous quarter ended March 2025. Sales rose 136.40% to Rs 776.25 crore in the quarter ended March 2026 as against Rs 328.36 crore during the previous quarter ended March 2025. For the full year,net profit rose 39.94% to Rs 364.00 crore in the year ended March 2026 as against Rs 260.11 crore during the previous year ended March 2025. Sales rose 36.98% to Rs 2022.99 crore in the year ended March 2026 as against Rs 1476.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales776.25328.36 136 2022.991476.84 37 OPM %39.5915.56 -28.4021.89 - PBDT312.5856.19 456 580.72335.48 73 PBT287.4939.30 632 488.98269.93 81 NP212.6727.81 665 364.00260.11 40 Powered by Capital Market - Live

Neuland Laboratories announced that the 42th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Neuland Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2026, inter alia, have recommended the final dividend of Rs 34 per equity Share (i.e. 340%) , subject to the approval of the shareholders.